We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+21.69%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$1.03B
AUM Growth
+$274M
Cap. Flow
+$156M
Cap. Flow %
15.15%
Top 10 Hldgs %
40.17%
Holding
97
New
37
Increased
20
Reduced
20
Closed
12

Top Buys

1
HRTX icon
Heron Therapeutics
HRTX
+$29.8M
2
TVTX icon
Travere Therapeutics
TVTX
+$24.7M
3
CTRX
CATAMARAN CORP COM STK (CDA)
CTRX
+$22.5M
4
AEGR
Aegerion Pharmaceuticals
AEGR
+$20.5M
5
EBS icon
Emergent Biosolutions
EBS
+$18.5M

Top Sells

1
LCI
Lannett Company, Inc.
LCI
+$25.5M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$25.4M
3
ASRT
Assertio
ASRT
+$19.7M
4
NVDQ
Novadaq Technologies Inc.
NVDQ
+$14.7M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$14.7M

Sector Composition

1 Healthcare 79.95%
2 Technology 0.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVDL
1
DELISTED
Avadel Pharmaceuticals
AVDL
$70.6M 6.84%
5,267,911
+1,500,000
+40% +$16.1M
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$65.1M 6.31%
4,305,469
+48,000
+1% +$542K
ASRT
3
DELISTED
Assertio
ASRT
$46.3M 4.48%
53,180
-25,900
-33% -$19.7M
EBS icon
4
Emergent Biosolutions
EBS
$394M
$45.6M 4.42%
1,805,352
+731,304
+68% +$18.5M
ANGO icon
5
AngioDynamics
ANGO
$558M
$40.8M 3.96%
2,592,649
+95,600
+4% +$1.56M
TVTX icon
6
Travere Therapeutics
TVTX
$5.27B
$34.1M 3.31%
+1,609,696
New +$24.7M
HRTX icon
7
Heron Therapeutics
HRTX
$89.1M
$31.1M 3.01%
+2,233,173
New +$29.8M
BDSI
8
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$29.3M 2.84%
3,472,054
+1,250,000
+56% +$10.1M
NVDQ
9
DELISTED
Novadaq Technologies Inc.
NVDQ
$27.3M 2.65%
1,226,617
-743,017
-38% -$14.7M
LCI
10
DELISTED
Lannett Company, Inc.
LCI
$24.4M 2.37%
170,891
-164,095
-49% -$25.5M
PGNX
11
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$22.8M 2.21%
5,586,169
+1,586,169
+40% +$8.11M
TTPH
12
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$21.9M 2.12%
100,406
-9,260
-8% -$2.58M
DSCI
13
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$21.2M 2.05%
1,669,777
+798,179
+92% +$10.3M
RIGL icon
14
Rigel Pharmaceuticals
RIGL
$750M
$21.2M 2.05%
545,512
+50,000
+10% +$1.78M
CTRX
15
DELISTED
CATAMARAN CORP COM STK (CDA)
CTRX
$21M 2.03%
+468,263
New +$22.5M
ANAC
16
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$20M 1.94%
1,000,869
-516,362
-34% -$10M
NTUS
17
DELISTED
Natus Medical Inc
NTUS
$19.7M 1.91%
764,915
-249,201
-25% -$6.28M
WINT
18
DELISTED
Windtree Therapeutics Inc
WINT
$17.3M 1.68%
576,143
– –
AMAG
19
DELISTED
AMAG Pharmaceuticals
AMAG
$16.8M 1.63%
+867,117
New +$18.4M
IPXL
20
DELISTED
Impax Laboratories, Inc.
IPXL
$16.7M 1.62%
633,929
-100,000
-14% -$2.5M
AEGR
21
DELISTED
Aegerion Pharmaceuticals
AEGR
$16.2M 1.57%
+350,000
New +$20.5M
INFI
22
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$15.8M 1.53%
1,326,000
+330,000
+33% +$4.43M
TEVA icon
23
Teva Pharmaceuticals
TEVA
$37.3B
$15.4M 1.49%
291,636
-550,100
-65% -$25.4M
PTX
24
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$15M 1.45%
+350,000
New +$11.6M
ZGNX
25
DELISTED
Zogenix, Inc.
ZGNX
$14.6M 1.42%
642,206
-92,204
-13% -$3M
1
2 3 4

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q1 2014 Portfolio in Review

As of Q1 2014, Broadfin Capital held 97 positions worth $1.03B, up 36% from $758M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Broadfin Capital deployed $156M of net new capital in Q1 2014, opening 37 new positions and adding to 20 existing holdings. Its largest new stake was Heron Therapeutics: 2,233,173 shares worth $31.1M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 76% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Lannett Company, Inc., an estimated $25.5M trimmed.

  • Broadfin Capital's largest Q1 2014 buy was Heron Therapeutics: 2,233,173 shares worth $31.1M.
  • Broadfin Capital added most to Emergent Biosolutions in Q1 2014, an estimated $18.5M increase.
  • Broadfin Capital's biggest Q1 2014 reduction was Lannett Company, Inc., cutting an estimated $25.5M.
  • Broadfin Capital fully exited NPS PHARMACEUTICALS INC in Q1 2014, selling an estimated $12.1M.
  • Broadfin Capital's ten largest holdings make up 40% of its $1.03B portfolio in Q1 2014.
  • Broadfin Capital opened 37 new positions and closed 12 in Q1 2014.
  • Broadfin Capital's portfolio value rose 36% quarter-over-quarter to $1.03B.

Based on Broadfin Capital's 13F filing for Q1 2014, filed 15 May 2014.